Kornimate/medical-research-clean huggingface dataset:
effect of california tri-pull taping method on shoulder subluxation, pain, active range of motion and upper limb functional recovery after stroke - a pre test post test design

Conditions: Post Stroke Shoulder Subluxation

Summary: this study was conducted to check the effect of california tri-pull taping method on post stroke shoulder subluxation, prior to conduct a large randomized clinical trial this study was conducted, and the result of the study was promising for the treatment of shoulder subluxation.

intervention was given by the lead researcher who was trained for the taping techniques. prior to give taping method participants who have hair around the shoulder was instructed to remove hair. two types of tape was used, a self-adhesive 1.5" cotton undercover tape (vpk, chennai) and a 1" rigid strapping tape (vpk, chennai). to approximate the humeral head into the glenoid cavity participants were instructed to place their affected arm on a wooden table. three piece of tape was used, firstly the investigators applied cotton undercover pre tape and then the investigators applied the rigid post tape on it. first piece (middle) of tape was applied from 1.5 inches below the deltoid tuberosity up to 2 inches above the glenoid cavity. second piece (posterior) was applied from 1.5 inches below the deltoid tuberosity upto the 1.5 inches above the mid spine of scapula. third piece (anterior) was applied from the 1.5 inches below the deltoid tuberosity upto the 1.5 inches above the clavicle. (figure-1). the tape was removed and new tape applied every monday, wednesday, and friday and remained on the patient for 6 consecutive weeks. all the participants were received standardized conventional neuro rehabilitation programme. the conventional neuro rehabilitation treatment includes, active, and passive range of motion exercise, bilateral activation of pectoralis major, activation of lattisimus dorsi, activation of the retractors, weight bearing exercise of upper extremity, activation of supraspinatus, reaching activities, grasping, holding and release, and adl activities. every participant was received conventional neuro rehabilitation for 45 minutes and 5 days a week.

Eligibility criteria:
inclusion criteria: 1. acute stroke 2. a minimum of 5 mm (0.2 in.) shoulder subluxation in the involved upper extremity. 3. mmse score ˃ 23. 4. age (35-70 yrs.) and of either sex. exclusion criteria: 1. mmse score ˂23. 2. other musculoskeletal disorder of the affected upper extremity. 3. history of trauma to the affected upper extremity. 4. hyper or hypo sensitivity disorders. 5. any skin allergy. 6. individual affected from neurological disorder other than stroke. 7. un-cooperative patients. 8. individuals with psychosomatic disorder.
study of personalized allocation of defibrillators in non-ischemic heart failure (spanish-1)

Conditions: Non-ischemic Dilated Cardiomyopathy

Summary: prospective, randomised, multicentre, open-label study to assess the non-inferiority of a personalised precision strategy for sudden cardiac death (scd) prevention in patients with non-ischemic dilated cardiomyopathy with left ventricular ejection fraction (lvef) ≤35%

prospective, randomised, multicentre, open-label study to assess the non-inferiority of a personalised precision strategy for scd prevention in patients with non-ischemic dilated cardiomyopathy with lvef≤35% randomization will be 1:1 and patients are allocated to either control strategy or intervention strategy. in the control strategy group, patients will get an implantable cardioverter defibrillator (icd) implanted. patients allocated to the intervention strategy will receive an icd according to genetic and cmr results. icd implantation criteria in patients allocated to the personalised strategy group will be the presence of either a dilated cardiomyopathy dcm-causing pathogenic or likely pathogenic genetic variants or late gadolinium enhancement (lge) in cardiac magnetic resonance (cmr). patients without dcm-associated genetic variants and without lge on cmr will not receive standard treatment but an icd will not be implanted on them.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years at the time of screening. * previously established diagnosis of non-ischemic dcm * optimised medical treatment at maximum tolerated doses for at least 3 months prior to the screening date. * nyha functional class ii-iii. * lvef ≤ 35% documented by cmr as study procedure. * life expectancy greater than 12 months. exclusion criteria: * history of coronary artery disease justifying the presence of ventricular dysfunction, defined as: history of coronary revascularisation or presence of significant coronary stenosis (≥50% in left main or ≥70% in a major epicardial artery) on invasive or non-invasive coronary angiography (coronary ct) * left ventricular dysfunction attributed to congenital heart disease, valvular disease, alcohol abuse or chemotherapy. * hypertrophic or infiltrative cardiomyopathy, active myocarditis or constrictive pericarditis. * history of recovered sudden death or sustained ventricular tachycardia. * nyha functional class iv. * waiting list for cardiac transplantation in emergency 0. * receiver of a solid organ transplant (lung, liver, heart or kidney).
a study of jnj-73763989, jnj-56136379, nucleos(t)ide analogs, and pegylated interferon alpha-2a in virologically suppressed participants with chronic hepatitis b virus infection

Conditions: Hepatitis B, Chronic

Summary: the purpose of this study is to evaluate the efficacy in terms of hepatitis b surface antigen (hbsag) levels of the study intervention (that is, jnj-73763989 + jnj-56136379 + nucleos\[t\]ide analog \[na\] and pegylated interferon alpha-2a \[pegifn-alpha2a\]).

this study is an intervention specific appendix to the hepatitis b wings platform trial (platformpahpb2001). the study title reflects the original study design and jnj-56136379 (jnj-6379) was initially part of the study intervention but has been removed as part of amendment 3 of the study.

Eligibility criteria:
inclusion criteria: * chronic hepatitis b virus (hbv) infection, hepatitis b e antigen (hbeag) positive or negative with suppressed viral replication under nucleos(t)ide analogue treatment for at least 6 months prior to screening * medically stable based on physical examination, medical history, vital signs, and 12-lead electrocardiogram (ecg) performed at screening * body mass index (bmi) between 18.0 and 35.0 kilogram per meter square (kg/m\^2), extremes included * must have serum hbsag greater than (\>) 100 international units per milliliter (iu/ml) at screening, as assessed by quantitative hbsag assay * must have a fibroscan stiffness measurement less than or equal to (\<=) 9.0 kilopascal (kpa) at screening exclusion criteria: * evidence of hepatitis a, c, d or e virus infection or human immunodeficiency, virus type 1 (hiv) or hiv-2 infection at screening * history or evidence of clinical signs or symptoms of hepatic decompensation, including but not limited to: portal hypertension, ascites, hepatic encephalopathy, esophageal varices * evidence of liver disease of non-hbv etiology * participants with a history of malignancy within 5 years before screening * contraindications to the use of pegylated interferon alpha-2a
feasibility of patient selection and treatment of head-neck cancer with proton therapy in denmark

Conditions: Head-and-neck Cancer

Summary: a study to investigate feasibility of local selection of patients with squamous cell carcinoma of the pharynx or larynx using anticipated benefit of proton radiotherapy in reducing the risk of late dysphagia or xerostomia.

in preparation for a randomised study in denmark (dahanca 35) the feasibility of selecting newly diagnosed patients with squamous cell carcinoma of the pharynx or larynx for proton therapy at the local treatment centers is investigated. a proton and a photon doseplan is prepared for patients planned for primary radiotherapy . if proton radiotherapy reduces the anticipated absolute risk of dysphagia \>= grade 2 (dahanca scale and/or xerostomia \>= grade 2 (eortc head-neck 35) with a clinical relevant value the patient is offered proton therapy at the danish center for particle therapy. the anticipated risk of xerostomia and dysphagia is estimated using normal-tissue complication models (ntcp). at least five patients from each of the six danish centers are required in this feasibility study.

Eligibility criteria:
inclusion criteria: patients with histologically proven squamous cell carcinoma of the pharynx or larynx planned for primary radiotherapy with curative intent a predicted clinical significant reduction in the risk of any of the two primary endpoints (\>= grade 2 observer-rated dysphagia or grade 2 patient-reported xerostomia) after proton therapy compared to photon therapy based on comparison of the individual patient dose plans no current or earlier malignancies, which may influence treatment, evaluation or outcome of the head-neck cancer informed consent as required by law above 18 years of age exclusion criteria: patient with cancers of the glottic larynx (stage i/ii), skull base, sino-nasal area, nasopharynx, unknown primary tumor and prior malignancies. patients with contraindications for proton therapy (as per 2019 pacemakers, implanted defibrillators and tracheostomy) inability to attend full course of radiotherapy or follow-up visits in the outpatient clinic distant metastasis previous radiotherapy of the head and neck previous surgery for the primary cancer with curative intent

Keywords: proton radiotherapy
evaluation of the use of an e-health therapeutic education application for osteoarthritis patients

Conditions: Osteo Arthritis Knee

Summary: osteoarthritis is the most common joint disease affecting the joint in a comprehensive and progressive manner. it leads to increasing disability. the recommendations of recent years favor the non-pharmacological treatment of osteoarthritis including regular physical activity, therapeutic education and weight loss osteoarthritis population has a low level of physical activity due to a lack of information, motivation and false beliefs related to physical activity and kinesiophobia (fear of movement) a preliminary qualitative study (arthe1) evaluating the barriers and levers of the use of an e-health therapeutic education application in patients with osteoarthritis was carried out in order to guide the development of the arthe application. the objective of this study is to have the application tested on a panel of patients in order to assess the benefits of using the application in terms of adherence to the practice of physical activity but also in clinical terms on function and pain, and the satisfaction of the patient

this is a prospective observational study including the evaluation of the use of the arth-e application after 3 weeks, 6 weeks and 3 months of use. patient recruitment will be done in the prm department of clermont-ferrand university hospital a subgroup of patients will receive a garmin vivosmart 4 connected wristband, which will record intrinsic stress measurement data during the test.

Eligibility criteria:
inclusion criteria: * patients older than 18 years * patients with osteoarthritis according to the acr (american college of rheumatology) criteria, symptomatic and diagnosed before inclusion by a specialist or not. * patients with least one knee impairment * patients with a smartphone or tablet with at least android 5 or ios 11. * volunteer patients willing to participate in the study. exclusion criteria: * patients with no diagnostic criteria for acr. * patients with comprehension disorders making it impossible to interview and complete questionnaires or use the application. * refusal to participate or being already included in a research protocol that could influence the current protocol. * patients under guardianship, curatorship or deprived of liberty.

Keywords: osteoarthritis gonarthrosis smarthpone application e-health
panitumumab plus folfiri in first-line treatment of metastatic colorectal cancer

Conditions: Metastatic Colorectal Cancer

Summary: to estimate the effect of kras mutation status (wild-type versus mutant) on objective response rate and other measures of efficacy for patients treated with panitumumab in combination with a chemotherapy regimen of irinotecan, 5-fluorouracil, and leucovorin (folfiri) as first-line therapy for metastatic colorectal cancer (mcrc).


Eligibility criteria:
inclusion criteria: * diagnosed with histologically- or cytologically-confirmed metastatic adenocarcinoma of the colon and/or rectum. * measurable disease according to modified recist guidelines. * eastern cooperative oncology group (ecog) performance status of 0, 1 or 2. * paraffin-embedded tissue or unstained tumour slides from primary or metastatic tumour available for central lab analysis. * adequate haematologic, renal, hepatic and metabolic function. exclusion criteria: * central nervous system metastases. * prior systemic therapy for the treatment of metastatic colorectal carcinoma with the exception of adjuvant fluoropyrimidine-based chemotherapy given at least six months prior to initiating study treatment. * prior anti-epidermal growth factor receptor (egfr) antibody therapy (e.g. cetuximab) or treatment with small molecule egfr tyrosine kinase inhibitors (e.g. erlotinib). * prior radiotherapy within 14 days prior to screening, and for which all signs of early radiological toxicity have not abated. * significant cardiovascular disease including unstable angina or myocardial infarction within six months before initiating study treatment or a history of ventricular arrhythmia. * history of interstitial pneumonitis or pulmonary fibrosis or evidence of interstitial pneumonitis or pulmonary fibrosis on baseline chest computed tomography (ct scan. * active inflammatory bowel disease or other bowel disease causing chronic diarrhoea (defined as \> 4 loose stools per day). * history of gilbert's syndrome or dihydropyrimidine deficiency. * known positive test for human immunodeficiency virus infection, hepatitis c virus, chronic active hepatitis b infection. * any investigational agent within 30 days before initiation of study treatment. * must not have had a major surgical procedure within 28 days prior to initiation of study treatment. * subject who is pregnant or breast-feeding. * woman or man of childbearing potential not consenting to use adequate contraceptive precautions during the course of the study and for six months after the last study drug administration for women, and one month for men. * other protocol specified criteria and specific details may apply.
effect of active-passive trainer cycling on multiple sclerosis

Conditions: Multiple Sclerosis

Summary: this randomised controlled trial aims to explore the effectiveness of a four week programme of exercise using lower limb active passive trainer (apt) (motomed trainer) in terms of spasticity in people with moderate to severe multiple sclerosis.

exercise is beneficial for people with multiple sclerosis (pwms). however, exercise options for those with moderate to high levels of disability are limited. cycling, delivered with an active passive trainer (apt) is one exercise option often offered within rehabilitation/exercise settings and many pwms buy apts for home use. anecdotally, pwms report they feel better and their spasticity reduces after apt cycling, however there is a lack of evidence to support this. 30 pwms will be recruited from the physical disability rehabilitation unit at the queen elizabeth university hospital, glasgow, and randomised to apt + usual care or usual care only. those in the apt group will receive 30 minutes of apt (2 mins passive warm up, 26 mins active cycling and 2 mins passive cool down), five days per week for 4 weeks. outcome measures will be cardiovascular fitness measured using the oxygen uptake efficiency slope (oues), spasticity assessed by modified ashworth scale (mas) and the multiple sclerosis spasticity scale (msss-88), function assessed by the functional independence measure (fim) and the timed 25 foot walk test (t25fw), quality of life measured by msqol-54. outcome measures will be assessed in both groups before and after the 4 week intervention period. symmetry, distance cycled and power will be recorded following each cycling session in the intervention group.

Eligibility criteria:
inclusion criteria: * have a confirmed diagnosis of progressive ms * are aged over 18 years * have an expanded disability status scale (edss) of between 6.5 (requires two walking aids - pair of canes, crutches, etc - to walk about 20m without resting) and 8.5 (essentially restricted to bed much of day); has some effective use of arms (retains some self care functions) and spasticity in their lower limbs (self reported) exclusion criteria: * cognitive impairment (cannot understand instructions) * other co-morbidities which would preclude them taking part in exercise * visual impairment (such that they cannot see the screen on the apt)

Keywords: muscle spasticity
the pour (postoperative urinary retention) study

Conditions: Postoperative Urinary Retention

Summary: the primary aim of this study will be to compare the rate of postoperative urinary retention between patients receiving sugammadex and those receiving traditional reversal agents

postoperative urinary retention following laparoscopic inguinal hernia repair occurs in approximately one out of ten patients. the more rapid reversal of neuromuscular blockade with sugammadex has empirically been associated with low rates of postoperative urinary retention. in this study, patients will receive sugammadex following laparoscopic inguinal hernia repair and then be retrospectively matched against a group of patients who did not receive sugammadex. the primary aim of this study will be to compare the rate of postoperative urinary retention between patients receiving sugammadex and those receiving traditional reversal agents (e.g. neostigmine which has a retention rate of 5-11%). we will also examine difference in cost and quality of life between the two groups. our hypothesis is that the use of sugammadex will decrease rate of postoperative urinary retention, decrease associated cost, such as need for admission, and not negatively impact quality of life.

Eligibility criteria:
inclusion criteria: * over the age of 18 * undergoing laparoscopic inguinal hernia repair at carolinas medical center by attending surgeons within the division of gastrointestinal and minimally invasive surgery * unilateral or bilateral inguinal hernia repair; may have concurrent umbilical hernia repair performed * agreeable to participation in the study exclusion criteria: * patients who are having concurrent ventral or flank hernias repaired at time of operation or are having an inguinal hernia repair along with another operation (e.g. laparoscopic cholecystectomy) * end-stage renal disease (creatinine clearance less than 30) * neuromuscular disease * prior adverse reactions to sugammadex * patients who do not provide consent for the study

Keywords: sugammadex
quantitative ultrasonography (us) evaluation on femoral condyle cartilage

Conditions: Osteoarthritis

Summary: the purpose of this study is to investigate the feasibility of using quantitative ultrasonography (us) evaluation to determine the severity of osteoarthritic femoral condyle cartilage erosion.


Eligibility criteria:
inclusion criteria: * patients with knee oa who were going to receive total knee arthroplasty exclusion criteria: * patients with inflammatory arthritis (e.g. rheumatic arthritis) and infectious disease (e.g. hepatitis b)

Keywords: ultrasonography knee early degeneration cartilage
remote physical activity monitoring in individuals with metabolic syndrome

Conditions: Metabolic Syndrome

Summary: a prospective intervention study to evaluate the effectiveness of the developed toolset for remote physical activity monitoring to improve arterial stiffness and other cardiometabolic parameters and to increase physical activity levels and the compliance to the prescribed exercise in individuals with metabolic syndrome.

at first, all subjects of the prospective study participated in the 2-month outpatient aerobic exercise program, which consisted of 40 aerobic training sessions on a cycle ergometer 5 times/week for 40 min. during all training sessions, heart rate was maintained at the targeted level, which was obtained individually by cardiopulmonary test. after 2 months, during individual motivational consultations, all participants received recommendations for home-based training and were randomly allocated to the intervention or the control group. then only the intervention group subjects participated in the 6-month home-based aerobic exercise program using a wearable heart rate monitor, which was connected to the smartphone via bluetooth. the intervention group subjects used a smartphone application created for the study. the control group participants were asked to exercise at home for 6 months without wearables and smartphone application. the evaluation of the study participants was performed at baseline (1st visit), after 2 months (2nd visit) and after 8 months (3rd visit).

Eligibility criteria:
inclusion criteria: * males (40-55 years) and females (50-65 years) with metabolic syndrome, having at least three of the following five criteria: hypertriglyceridemia (triglycerides ≥ 1.7 mmol/l); high-density lipoprotein cholesterol ≤ 1.03 mmol/l for men or ≤ 1.29 mmol/l for women; abdominal obesity (waist circumference \> 102 cm for men and \> 88 cm for women); elevated blood pressure (systolic blood pressure ≥ 130 mmhg and/or diastolic blood pressure ≥ 85 mmhg or current use of antihypertensive drugs); elevated fasting plasma glucose ≥ 5.6 mmol/l; exclusion criteria: * patients with overt cardiovascular disease (previous myocardial infarction, coronary artery bypass surgery, percutaneous coronary intervention, previous stroke) * patients with severe heart failure symptoms, uncontrolled hypertension * patients with urinary tract infection or fever for another unknown reason * patients who have actively exercised in the last 24 hours * pregnant women

Keywords: metabolic syndrome physical activity telemonitoring smartphone application wearables cardiovascular prevention mhealth digital health